Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Payables: 2011-2024

Historic Payables for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $1.2 million.

  • RedHill Biopharma's Payables fell 56.33% to $835,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $7.2 million, marking a year-over-year decrease of 43.22%. This contributed to the annual value of $1.2 million for FY2024, which is 64.37% down from last year.
  • Latest data reveals that RedHill Biopharma reported Payables of $1.2 million as of FY2024, which was down 64.37% from $3.3 million recorded in FY2023.
  • In the past 5 years, RedHill Biopharma's Payables registered a high of $119.4 million during FY2022, and its lowest value of $1.2 million during FY2024.
  • Its 3-year average for Payables is $41.3 million, with a median of $3.3 million in 2023.
  • As far as peak fluctuations go, RedHill Biopharma's Payables soared by 2,121.30% in 2020, and later plummeted by 97.26% in 2023.
  • Yearly analysis of 5 years shows RedHill Biopharma's Payables stood at $92.9 million in 2020, then rose by 2.52% to $95.3 million in 2021, then rose by 25.36% to $119.4 million in 2022, then crashed by 97.26% to $3.3 million in 2023, then plummeted by 64.37% to $1.2 million in 2024.